

REPROS THERAPEUTICS INC.

Form 8-K

April 05, 2007

**Table of Contents**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**Current Report Filed Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

**Date of Report**

**(Date of earliest event reported): April 5, 2007**

**Repos Therapeutics Inc.**

**(Exact name of registrant as specified in its charter)**

|  |   |  |
|--|---|--|
| <b>Delaware</b><br><b>(State or other jurisdiction of<br/>incorporation or organization)</b> | <b>001-15281</b><br><b>(Commission File Number)</b> | <b>76-0233274</b><br><b>(I.R.S. Employer Identification<br/>No.)</b> |
|--|---|--|

**2408 Timberloch Place, Suite B-7**

**The Woodlands, Texas 77380**

**(Address of principal  
executive offices  
and zip code)**

**(281) 719-3400**

**(Registrant's telephone  
number, including area  
code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 7.01. Regulation FD Disclosure

Item 9.01. Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

Press Release

---

**Table of Contents**

**Item 7.01. Regulation FD Disclosure**

The information in this Current Report is being furnished pursuant to Item 7.01 of Form 8-K and, according to general instruction B.2. thereunder, the information in this Current Report shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933.

Repros Therapeutics Inc. (the Company ) announced today that Joseph Podolski, President and CEO of the Company, will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Thursday, April 12, 2007 at 12:45 p.m. Eastern Time at the Millennium Broadway Hotel in New York City. This presentation will be webcast live and subsequently archived for 30 days on the company s website <http://www.reprosrx.com> under the Presentations tab. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time.

A copy of the Company s press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

**Item 9.01. Financial Statements and Exhibits**

c. Exhibits

Exhibit

| Number | Description                        |
|--------|------------------------------------|
| 99.1   | Press Release dated April 5, 2007. |

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Repros Therapeutics Inc.**

Date: April 5, 2007.

By: /s/ Louis Ploth, Jr.  
Louis Ploth, Jr.  
Vice President, Business Development  
and Chief Financial Officer

---

**Table of Contents**

**EXHIBIT INDEX**

| Exhibit<br>Number | Description                        |
|-------------------|------------------------------------|
| 99.1              | Press Release dated April 5, 2007. |